ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2252

Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer

Michelle Nguyen1, Aaron Baraff2, Alexander Peterson2, Alexandra Schmidt2, Katherine Wysham3, Aliyah Pabani4, Carolyn Presley5, Nicholas Smith1, Shelly Gray1, Jose Garcia6, Ariela Orkaby7 and Namrata Singh1, 1University of Washington, Seattle, WA, 2VA Puget Sound Health Care System, Seattle, WA, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Johns Hopkins, Washington, DC, 5Ohio State University Medical Center, Columbus, 6VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, 7VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA

Meeting: ACR Convergence 2025

Keywords: Aging, Comorbidity, Oncology, rheumatoid arthritis, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Individuals with rheumatoid arthritis (RA) have a higher prevalence of frailty, even at younger ages, compared to the general population1. Among persons with lung cancer, frailty is associated with decreased survival2. However, this association has not yet been assessed among patients with lung cancer and pre-existing RA. The objective of this study was to better characterize the contribution of frailty to survival differences among older adults with RA and lung cancer.

Methods: Using nationwide electronic medical records data from the Veterans Health Administration, we included patients aged ≥ 50 years with a lung cancer diagnosis. RA was defined by ≥ 2 RA ICD-9/10 codes 1–365 days apart prior to cancer diagnosis. The validated Veterans Affairs Frailty Index (VA-FI) was used to characterize patient’s frailty status. VA-FI is a validated electronic frailty index developed to measure frailty using administrative claims and electronic health records data in Veterans. Patients were characterized as robust, pre-frail, or frail. Cox proportional hazards regression models were used to assess the association between frailty status and survival, adjusting for demographics, smoking history, rheumatic disease comorbidity index (RDCI), prior cancer history, and tumor stage.

Results: We identified 2,864 patients with pre-existing RA and lung cancer; 77.7% were > 65 years, 94.9% were male, 79.2% were White, 93.1% non-Hispanic. Based on the VA-FI, 34% were categorized as robust, 26% pre-frail, and 39% frail (Table 1). Age-adjusted mortality rates per 1,000 person-years were 403.3 for robust, 398.9 for pre-frail, and 410.8 for frail patients. In multivariable analysis, compared with robust persons, pre-fail persons had a mild increased risk of mortality (aHR 1.11; 95% CI: 1.00-1.24), while frail patients had a statistically significant higher risk (aHR 1.27; 95% CI: 1.12-1.43) (Table 2).

Conclusion: Among Veterans with RA and lung cancer, frailty was common and associated with worse survival. These findings highlight the prognostic importance of frailty and suggest it may be routinely assessed to guide risk stratification and clinical decision-making in this population.

Supporting image 1Table 1: Baseline Characteristics of Patients with RA and Frailty Veterans Affairs Frailty Index

Supporting image 2Table 2: Age-Adjusted Mortality Rates and Multivariable Adjusted Hazard Ratio


Disclosures: M. Nguyen: None; A. Baraff: None; A. Peterson: None; A. Schmidt: None; K. Wysham: None; A. Pabani: None; C. Presley: None; N. Smith: None; S. Gray: None; J. Garcia: Aveo Oncology, 2, Catalym, 2, Pfizer, 5; A. Orkaby: None; N. Singh: None.

To cite this abstract in AMA style:

Nguyen M, Baraff A, Peterson A, Schmidt A, Wysham K, Pabani A, Presley C, Smith N, Gray S, Garcia J, Orkaby A, Singh N. Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/association-between-frailty-and-survival-among-older-adults-with-rheumatoid-arthritis-and-lung-cancer/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-frailty-and-survival-among-older-adults-with-rheumatoid-arthritis-and-lung-cancer/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology